Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York.
Oper Neurosurg (Hagerstown). 2018 Aug 1;15(2):184-193. doi: 10.1093/ons/opx205.
BACKGROUND: The use of intraoperative navigation during microscope cases can be limited when attention needs to be divided between the operative field and the navigation screens. Heads-up display (HUD), also referred to as augmented reality, permits visualization of navigation information during surgery workflow. OBJECTIVE: To detail our initial experience with HUD. METHODS: We retrospectively reviewed patients who underwent HUD-assisted surgery from April 2016 through April 2017. All lesions were assessed for accuracy and those from the latter half of the study were assessed for utility. RESULTS: Seventy-nine patients with 84 pathologies were included. Pathologies included aneurysms (14), arteriovenous malformations (6), cavernous malformations (5), intracranial stenosis (3), meningiomas (27), metastasis (4), craniopharygniomas (4), gliomas (4), schwannomas (3), epidermoid/dermoids (3), pituitary adenomas (2) hemangioblastoma (2), choroid plexus papilloma (1), lymphoma (1), osteoblastoma (1), clival chordoma (1), cerebrospinal fluid leak (1), abscess (1), and a cerebellopontine angle Teflon granuloma (1). Fifty-nine lesions were deep and 25 were superficial. Structures identified included the lesion (81), vessels (48), and nerves/brain tissue (31). Accuracy was deemed excellent (71.4%), good (20.2%), or poor (8.3%). Deep lesions were less likely to have excellent accuracy (P = .029). HUD was used during bed/head positioning (50.0%), skin incision (17.3%), craniotomy (23.1%), dural opening (26.9%), corticectomy (13.5%), arachnoid opening (36.5%), and intracranial drilling (13.5%). HUD was deactivated at some point during the surgery in 59.6% of cases. There were no complications related to HUD use. CONCLUSION: HUD can be safely used for a wide variety of vascular and oncologic intracranial pathologies and can be utilized during multiple stages of surgery.
背景:在显微镜手术中使用术中导航时,如果需要在手术视野和导航屏幕之间分配注意力,那么导航的使用可能会受到限制。抬头显示器(HUD),也称为增强现实,允许在手术流程中查看导航信息。 目的:详细介绍我们使用 HUD 的初步经验。 方法:我们回顾性分析了 2016 年 4 月至 2017 年 4 月期间接受 HUD 辅助手术的患者。所有病变均评估了准确性,并且对研究后半段的病变评估了其效用。 结果:共纳入 79 例患者的 84 种病变。病变包括动脉瘤(14 个)、动静脉畸形(6 个)、海绵状畸形(5 个)、颅内狭窄(3 个)、脑膜瘤(27 个)、转移瘤(4 个)、颅咽管瘤(4 个)、神经胶质瘤(4 个)、神经鞘瘤(3 个)、表皮样/皮样囊肿(3 个)、垂体腺瘤(2 个)、血管母细胞瘤(2 个)、脉络丛乳头状瘤(1 个)、淋巴瘤(1 个)、骨母细胞瘤(1 个)、斜坡脊索瘤(1 个)、脑脊液漏(1 个)、脓肿(1 个)和桥小脑角 Teflon 肉芽肿(1 个)。59 个病变位于深部,25 个位于浅层。识别的结构包括病变(81%)、血管(48%)和神经/脑组织(31%)。准确性被认为是极好的(71.4%)、良好的(20.2%)或差的(8.3%)。深部病变的准确性较差(P =.029)。HUD 在 50.0%的病例中用于床/头定位、17.3%的病例中用于皮肤切口、23.1%的病例中用于开颅、26.9%的病例中用于硬脑膜切开、13.5%的病例中用于皮质切除、36.5%的病例中用于蛛网膜切开和 13.5%的病例中用于颅内钻孔。在 59.6%的病例中,HUD 在手术过程中的某个时间被停用。没有与 HUD 使用相关的并发症。 结论:HUD 可安全用于多种血管和颅内肿瘤病变,并可在手术的多个阶段使用。
Oper Neurosurg (Hagerstown). 2018-8-1
J Neurosurg. 2017-12-1
Oper Neurosurg (Hagerstown). 2017-2-1
Clin Neurol Neurosurg. 2015-6
World Neurosurg. 2016-3
Neurosurgery. 2014-6
J Clin Med. 2024-9-25
Oper Neurosurg (Hagerstown). 2023-12-26
Front Neurol. 2023-11-2
World Neurosurg. 2015-4
J Emerg Med. 2014-12
Acta Neurochir (Wien). 2014-9
J Diabetes Sci Technol. 2014-9
Neurosurgery. 2014-6
Neurosurgery. 2014-6